High materiality8/10
Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST)
Why it may matterVerify against the original reporting
Overweight rating reiterated; bullish longer-term setup.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Cantor Fitzgerald maintains an overweight rating on AQST with a target of $11. Current price is $5.27; price has declined by 4.84 since the signal.
- Overweight rating maintained; target $11; price $5.27; price down 4.84 since signal.
Key facts
- 01
Target: $11
- 02
Posted price: $5.27
- 03
Analyst firm: Cantor Fitzgerald
- 04
Analyst: Kristen Kluska
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.